Recombinant Human TFPI Protein(His tag) (HH0129TL)

Cat.No.

HH0129TL

Synonyms

TFPI; LACI; EPI; TFI; TFPI1;

Species

Human

Accession

TFPI

Source

HEK293

Tag

His

Predicted N Terminal

Asp 29

Form

Lyophilized from sterile PBS, pH 7.4, 5 % trehalose and 5 % mannitol.

Bio-activity

Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (Anaspec, Catalog#27114). The IC50 value is < 0.4 nM, as measured in 100μL reaction mixture containing 1.25 ng trypsin (Sigma, Catalog#T47

Molecular Mass

Recombinant Human TFPI comprises 265 amino acids with a predicted molecular mass of 30.6 kDa. As a result of glycosylation, the apparent molecular mass of rhTFPI is approximately 42-45 kDa in SDS-PAGE under reducing conditions.

Endotoxin

< 1.0 EU per 1 microgram of protein (determined by LAL method).

Purity

> 85 % by SDS-PAGE.

Background

Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.